click enter text
earn season ten cover us/eu pharmaceut
compani begin start thursday januari bristol-
myer end thursday februari astrazeneca report
contain updat forecast perspect
averag ep growth across coverag approxim
compound-annual-growth-rate basi exhibit averag growth rate us eu
compani roughli compar high varianc
compani reflect differ mix futur patent exposur pipelin
output increas product metric like phase transit success
rate remain fundament bright spot clearli
mean everi compani full pipelin drug price headwind us
continu actual price eros gradual least
view
prescript drug volum growth us across
biopharma compani flat y/i exhibit last
trend averag closer may reflect
manag care erect access hurdl net sale growth histor
correl well volum growth posit net price power
us net price power diminish shown prior
new report data look ex-u ja unit growth exhibit
rel stabl last unlik us
region net price tend move lower time gradual
price declin driven varieti mechan
may degre risk ep guidanc given
industri self-restraint take drug price increas
greater public scrutini howev impair lli guidanc
given decemb
four outperform-r stock azn novn one
under-perform inform stock cover
across us eu see global pharmaceut outlook
januari issu monthli controversi report
report limit sole use client wolf research pleas refer disclosur section locat end
www wolferesearch com/disclosur write us wolf research llc lexington avenu suit new york ny
analyst certif disclosur
page
 growth flat year-over-year last trend averag exhibit data
averag across biopharma compani us limit coverag univers clear
drive seem period dampen growth one plausibl contributor manag care access
consum out-of-pocket spend may reach tip point continu worsen
gradual time
eu japan growth roughli stabl last exhibit ja unit growth
last outpac eu unit growth nearli trend line rel stabl across period price
geographi tend declin time unlik us gener rise due greater price power
page
note retail unit use compar trx
note retail unit use compar trx
foreign exchang mid-sd headwind us compani low-sd headwind gsk san
drug compani report usd cover like see mid-sd headwind fx
usd appreci vi -- vi major currenc present tailwind compani report
major european currenc gsk san may off-set compani weak
emerg market key currenc includ real lira yuan rubl depreci exhibit show
usd rel eur gbp chf jpi
exhibit usd vs euro gbp swiss franc yen
eur chf gbp
page
us drug price expect continu gradual pressur varieti propos continu
promulg histori suggest mani like die vine scale back less
oner propos effect lobbi effort deep-pocket drug industri coupl
congression inertia impact reform measur gener requir act congress new
law much shorter list chang accomplish administr rule-mak
process hh agenc
commerci side payer dynam quit differ public program side price
govern principl natur competit oppos govern regul
misconcept think privat payer simpli follow footstep govern despit privat
commerci payer nonetheless effect foster signific price competit sever instanc
given heighten scrutini drug price increas like industri show restraint rel
prior period price increas flew beneath radar pose degre risk upcom
guidanc yet seem impair lli guidanc provid decemb despit lli high
exposur price-competit categori diabet
one risk contempl next presidenti cycl democrat take white hous
congress substant polici chang could enact go presidenti elect talk
medicar predict turn volum exact definit matter mean
abil buy-in medicar vs tradit commerci insur non-elderli consum like
impact instead mean singl payer system us would major neg
us healthcar industri overal realist consider
page
summari model chang slight downward revis averag everi compani
import contributor downward chang howev simpl advanc earli stage
factor attempt captur futur product flow drug compani pipelin distant out-year
everi year push forward one year revenu stream kick
exhibit show chang revenu ep forecast us european drug stock
cover
exhibit chang revenu ep forecast
page
compar growth outlook exhibit show revenu ep growth cover name
exhibit revenu ep growth rate index
page
valuat exhibit comp sheet coverag univers also shown repres compani
specialti pharmaceut sector
page
azn w/o europ healthcar compani comparison cover pharma target multiplediv yield
wolf bullet-point view
investor sentiment bifurc viewpoint love hate
pipelin prowess abil best phase pipelin optic look full
mani compound natur
binari event risk noth discret addit pipelin misstep rova-t failur would
hurt given imper lessen depend humira question anticip whether
pursu larger almost seem inevit question time
near-term outlook growth near-term decent question mark given recently-revis
steeper sale eros ex-u humira
long-term outlook good base model
valuat cheapest price-to-earnings lag peer summer rotat pharma
net remain cautiou due uncertainti impact humira
biosimilar admittedli consensu concern least among worri
singl product concentr risk degre vastli exce compani cover
product unfortun tail end life cycl odd name
competit growth next year substanti pressur earn begin think
margin de-lever under-model eu biosimilar humira launch sinc octob
belief new money sit one engag larger distinct possibl
otherwis get hand meaning new product perhap stori get interest
adjust currenc impact usd strengthen major currenc base movement
estim fx provid headwind abbv result continu strong headwind
first half
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut distant
out-year base compani spend use formula compani push
revenu stream forward annual creat model headwind compani rel prior
lower ex-u humira base higher expect price eros biosimilar us
slightli rais growth maintain growth
page
rais imbruvica revenu rais revenu base sale iqvia trend earlier line
expans cll sll pancreat other continu drive growth near term dont see
best-in-class btk product face threat launch gener btk
rais hcv revenu hcv revenu mainli mavyret rais us revenu believ
global sale peak expect sale declin slightli lower rate declin
pipelin lower upadacitinib revenu due late nda submiss us ex-u
rais revenu beyond
exhibit abbvi line item forecast model chang
page
astrazeneca azn outperform price
wolf bullet-point view azn
investor sentiment gener attract azn futur growth prospect understand avers
extern feel like cook book
pipelin prowess thin higher-risk compound bace anifrolumab
occur still variou opportun phase commonli view major pipelin stori
histor great compani
binari event risk volatil roxadustat cardiovascular safeti data earli
uk compani brexit add layer risk expect investor materi
near-term outlook decent usher revenu ep growth hope
valuat expens near-term ep price-to-earnings normal out-year given superior growth prospect
net continu like azn best long-term grower group turn around
margin expans stori new growth come already-approv product mean
azn heavili depend futur pipelin traction unpredict said azn still
late-stag pipelin opportun ahead overal investor expect overli high
like two aspect azn footprint china vastli greater compani
could sourc long-term competit advantag potenti azn could one day
take-out target one smaller compani sector recal pfe attempt
adjust currenc impact us dollar weaken major currenc fourth quarter
provid headwind earli stage factor advanc earli
stage factor one year factor account pipelin revenu contribut base current
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut distant
out-year base compani spend use formula compani push
revenu stream forward annual creat model headwind compani rel prior
adjust sobi divestitur follow novemb announc azn divest us
right synagi sobi remov product model begin
ad extern revenu account up-front consider product cash
equiti consider
page
slow lokelma launch us base slow trajectori current leader brand
hyperkalemia market vifor veltassa slow revenu ramp lokelma better reflect
challeng market
rais symbicort number rais symbicort estim reflect lack
gener competit quarter fda yet approv gener formul although time gener
entri unclear conserv model entri
extern revenu rais extern revenu account mileston receiv
upon fda approv lynparza ovarian cancer set
rais flumist revenu rais flumist revenu us soft comp given
flumist return market septemb repres truncat flu season prophylaxi
roxadustat follow posit phase data olympu rocki decemb
integr roxadustat estim begin current model peak sale
page
exhibit astrazeneca line item forecast model chang
page
wolf bullet-point view
investor sentiment unlov stock controversi rate io misstep hurt
includ us guard
pipelin prowess intern pipelin thin notabl higher-
confid asset offer upsid downsid given deservedly-low investor
expect propos celg merger bring greater number phase asset new
therapeut area includ hematolog repres cut edg scienc
binari event risk ye relat io news flow competitor never-end sourc
news seem also inherit celg binari event risk greatest sourc relat revlimid
near-term outlook financi result solid shape next sever quarter investor
expect opdivo overal clearli moder opdivo yervoy like continu
disappoint lung opdivo chemo find success potenti settlement on-going revlimid
patent litig dr reddi would posit event
long-term outlook organ growth clearli correl trajectori opdivo beyond
uncertainti point big debat celg revenu offer natur big buffer celg
combin compani could go ex-growth time-frame base current pro-forma model
valuat contract significantli price-to-earnings multipl best bmi celg
price-to-earnings multipl pro-forma ep lower abbv
net clearli controversi rate volatil
stock tie mishap immuno-oncolog space lost major lead
merck space continu controversi long-term trajectori opdivo
investor expect moder uncertainti price plausibl scenario opdivo
continu remain one two market lead therapi valu lung think
opdivo yervoy continu disappoint part data mayb mar/april earli
respect chemo combo work allow captur market share lung part
data mayb one import long-term sourc upsid option anti-pdx therapi
work earlier stage adjuv cancer set data come time-frame
still far away admittedli pend acquisit celg chang thing greatli add yet anoth
layer controversi given newco price-to-earnings pro-forma ep think upsid
exce downsid current level difficult us say support deal believ
decent share price upsid exist intermediate-term current level signific alpha would cours
gener anoth compani like came bid effect kill
celg transact odd rel low repres free option upsid
point deal closur
page
adjust currenc impact usd strengthen major currenc base
movement estim fx provid low-sd headwind result
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
upsa divestitur reduc estim intern geographi start account sale
upsa consum health taisho
opdivo increas estim slightli base strong sale trend price increas januari
page
exhibit bristol-my squibb line item forecast model chang stand-alon w/o celg
page
wolf bullet-point view
pipelin prowess histor one better organ late-stag pipelin
interest opportun promis tirzepatid
near-term outlook recent gave guidanc healthi well expect
long-term outlook solid one better long-term growth rate
valuat valuat second highest group azn
net come long way last sever year upgrad stock
heavili favor pendulum clearli swung stock consensu
buy re-launch wolf late peer-perform rate feel
risk reward evenli balanc strong run throughout year howev back strong
guidanc given decemb analyst day long-term outlook better initi
model leav well-posit compani substanti exposur diabet
revenu categori seem well posit rel peer also categori
price competit meaning
adjust currenc impact usd strengthen major currenc base
movement estim fx provid low-sd headwind lli result
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
loxo incorpor loxo model deal expect close end
dilut ep around turn accret accret reach
lartruvo drew revenu zero due failur fail phase
confirmatori trial indic longer promot lartruvo small compensatori
adjust made sg dilut ep around
smaller adjust made reflect chang im sale trend note made major
revis present guidanc decemb
page
exhibit eli lilli line item forecast model chang
page
wolf bullet-point view gsk
investor sentiment mix point view
pipelin prowess thinner side term late-stag product raw abil
total devoid bcma gsk promis turn around new leadership
binari event risk moder amount volatil anti-bcma data investor expect
medium commerci futur compound bullish uk compani brexit
add layer risk expect investor materi
near-term outlook stock volatil back tsro acquisit caus sell-off
consum jv format led share price rebound seem like quieter partli
much way catalyst ep growth neg due tsro dilut
trough hiv uncertainti remain due competit script trend need monitor
long-term outlook steadier ep growth trajectori yet ep still ep
becom pure play post consum health spin loe burden beyond advair compar
valuat price-to-earnings lower end peer group averag
net current level gsk face limit downsid risk pipelin thin
total devoid growth profil modest compani activ tri chang thing
win plaudit old new approach recent exampl includ commit
split newly-form consum health far away effect meaning chang
big organ like gsk easi histori show often fall flat patient valu investor gsk
may make sens especi dividend yield everyon els stori may feel ripe
enough hiv competit threat possibl chang payer dynam need monitor
adjust currenc impact usd gain pound emerg market currenc
weaken taken togeth estim fx provid low-sd headwind gsk
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
page
rais advair disku revenu us previous contempl gener advair disku us
yet receiv approv product conserv move gener entri
rais benlysta revenu long-term follow neg top-line data azn trial
anifrolumab sle rais long-term benlysta revenu reflect allevi
zejula indic expans rais zejula revenu potenti indic expans base
quadra data ovarian cancer regardless brca mutat statu would expand address
patient popul late-lin ovarian set
tivicay lower us revenu estim near longer term account slow
volum growth base iqvia data
incrus rais global peak sale estim account current growth trend
exhibit glaxosmithklin line item forecast model chang
page
wolf bullet-point view
investor sentiment morph consensu buy last year keytruda almost singular
pipelin prowess late-stag pipelin remain thin histor good core
compet deserv credit nearli flawless execut io continu outpac
binari event risk lower end mostli tie variou io trial readout remain
biggest competitor monitor like stay posit competitor even
lower posit could volatil engag larger
near-term outlook ep growth look competit bias upsid keytruda grow
faster expect also gardasil under-appreci near- long-term opportun
long-term outlook long-term outlook solidifi nice one stock
coverag capabl post doubl digit ep growth sever driver keytruda gardasil lynparza
possibl lenvima
valuat slightli averag price-to-earnings multipl basi
net becom consensu buy valuat still reason given
above-averag growth profil compar low event risk fulli expect
remain io compani addit driver industry-wid io upsid form adjuv
trial potenti under-model ex-u io opportun relev
well io compani percept one growth driver keytruda
requir re-think view gardasil second major futur growth driver think consensu
under-model tune sever billion dollar written recent furthermor
patent cliff vaccin meaning competit threat gardasil
horizon biggest challeng simpli manufactur enough satisfi demand
claim lynparza azn lenvima eisai under-appreci realli need
round stori late-stag pipelin thin moment pursu
 front answer remain elus
adjust currenc impact usd strengthen major currenc except yen
base movement estim fx provid headwind mrk result
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
page
model impact antelliq acquisit decemb merck announc acquisit antelliq
group anim health compani cash payment billion euro model impact
acquisit begin antelliq gener approxim million euro annual
grow quickli broader anim health industri
lower invanz revenu first full quarter gener competit mrk invanz par
ag launch juli addit entrant enter quarter acceler market share loss
last week quarter maintain market share base iqvia unit
gener nuvar impact base comment dr reddi regard gener nuvar approv
revenu contempl gener entri begin given lack remain
legal hurdl note complex product howev delay repres upsid
keytruda revenu rais us keytruda estim base increas convict
around leadership nsclc number potenti indic expans
page
exhibit merck line item forecast model chang
page
wolf bullet-point view novn
investor sentiment slowli turn coincid va take ceo
pipelin prowess abil solid afraid cut edg current late-stag
pipelin full sever compound larg de-risk still need finess approv launch well
near-term outlook good growth catalyst ahead keep investor engag
long-term outlook reason grower variou creat headwind
net like novarti one easier stori tell full pipelin
compar low risk profil reason growth new ceo va narasimhan execut quarterli
perform sinc take februari investor like one rare ceo hail
therefor abl talk detail pipelin identifi novarti top pick start
surprisingli favor sentiment steadili warm catalyst ahead includ
continu narrow focu alcon spin-out occasion rumbl get rid sandoz
variou pipelin approvals/launch entresto track well becom mani billion dollar product
investor alway hope jnj eclips trial come gone elimin overhang
part long-term growth reason great due variou futur perhap novarti
final becom aggress take cost system way boost ep may mere
pipe dream
adjust currenc impact usd strengthen major currenc base movement
estim headwind result
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
model impact sandoz divestitur aurobindo septemb novarti announc agreement
divest portfolio oral solid topic gener aurobindo model close
note busi gener sale subsequ rais sandoz
margin commodit product portfolio would like drag margin
page
alpelisib follow posit top-line data trial alpelisib
advanc metastat breast cancer ad alpelisib model begin
estim peak sale
zolgensma aka doubl peak sale estim zolgensma ww
exhibit novarti line item forecast model chang
page
wolf bullet-point view
investor sentiment gener support rare top pick
pipelin prowess abil histor weak phase pipelin arguabl look
better tafamidi perhap tangibl excit new product point tanezumab contrast
binari event risk noth signific call
near-term outlook ep growth flattish fairli quiet stori
long-term outlook ep growth flattish rebound moder level
valuat price-to-earnings multipl lower end group averagea often
net pfe pipelin improv growth next two year remain flattish
patent expir share expens new leadership
announc anyth chang substant probabl alreadi gone variou
iter restructur final piec dispos consum recent fell place
format jv gsk given long-term growth modest stori catalyst-lit
even better pipelin difficult see stock outperform defens rotat
could increment buyer low valuat offer downsid support
adjust currenc impact usd strengthen major currenc base
movement estim fx provid develop eu row em headwind pfe
result continu strong headwind first half
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
lower chantix revenu lower revenu base recent sale iqvia
script trend although gener expect enter us market market
south korea alreadi allow gener entri
lower ibranc revenu slightli lower us ibranc revenu base iqvia us script
lower expect sale ibranc also face increas competit pressur
novn monopoli expans adjuv set could potenti futur
page
lower lipitor revenu lower global revenu base continu steep loe
eros seen
lower lyrica revenu lower us revenu start due product go loe
expect higher eros rate forecast previous
rais prevnar revenu rais us revenu slightli product matur
growth flatten expect see pressur launch vaccin
exhibit pfizer line item forecast model chang
page
wolf bullet-point view
investor sentiment mix view tug-of-war pipelin bull align biosimilar risk
bear align
pipelin prowess best-in-class compani pipelin continu get even
interest oncolog non-oncolog area
binari event risk noth major come mind could stealth upsid surpris biosimilar
avastin/rituxan/herceptin delay us on-going patent litig
near-term outlook ep growth seem like flattish sure clariti emerg
battl oppos forc pipelin vs biosimilar
long-term outlook ep growth least model compress biosimilar eros across three
mega-brand give lowest ep compound-annual-growth-rate group
valuat price-to-earnings basi trade bottom half group
net strike versu peer compani breadth current
pipelin testament best-in-class compani unfortun belief despit
pipelin investor attent like overwhelm prospect roch three biggest drug
repres front end gener entri time clear fast
type product erod earli sign least ex-u promis bull argu
rog valuat alreadi reflect concern futur valu pipelin under-
estim possibl least current model earn estim begin trail consensu
fair degre make difficult name construct also make slowest
grower group next sever year name worth watch see thing evolv
urgenc step one upsid scenario biosimilar us get delay assert
infring varieti compani three major brand
adjust currenc impact chf strengthen major european currenc weaken
slightli usd estim net impact headwind revenu
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
tamiflu xofluza base prescript volum data tamiflu erod much quickli
previous model due avail seven gener formul roch switch patient
page
onto next-gen xofluza roch also launch xofluza earlier previous model ahead
flu season incorpor model begin
us biosimilar impact slow intermediate-term eros rituxan herceptin avastin
unit state given limit number entrant market format on-going litig roch
could lead delay beyond previous expect timelin
assum oper margin flattish contract
exhibit roch line item forecast model chang
page
 sale chf newsfr oldsfr gross margin sale bp chf newsfr oldsfr chf newsfr oldsfr chf newsfr oldsfr oper expens chf newsfr oldsfr oper margin bp net incom attribut roch chf newsfr oldsfr dilut ep chf newsfr oldsfr sfr
wolf bullet-point view san
investor sentiment interest build slowli base idea lantu declin wash
allow organ growth shine new cfo cut cost prior management team
pipelin prowess abil clearli weaker end histor current
pipelin thin san chang head step right direct whether san
fix remain tbd
binari event risk much major event think on-going praluent litig
could theoret lead product withdraw seem like low probabl outcom
near-term outlook ep growth rebound last three year flattish/down
bit light catalyst
long-term outlook steadi grower lower level per forecast
valuat among cheapest stock group price-to-earnings multipl basi
net given san lower valuat often case like lot
downsid risk stori extend period growth seem lag clear
san prospect histor among weakest sector get better anytim soon new
head hire sometim come month unveil vision futur
turn around fail often succe even succeed take long time
deeper invest mean spend could rise tried-and-tru quicker way gain
bigger pipelin earlier san spent purportedli earmark
acquisit two differ deal one introduc new uncertainti wont like enough
chang earn trajectori meaning enough view sit sidelin
adjust currenc impact usd strengthen major currenc base
movement estim fx provid low-sd headwind san result san guid
impact revenu fx
earli stage factor cover compani start new year advanc forward
earli stage factor one year factor account futur pipelin revenu contribut
distant out-year base compani spend use formula compani
push revenu stream forward annual creat model headwind compani rel
prior forecast
multaq estim increas account loss exclus come later
admelog increas us estim base stronger im trend
page
exhibit sanofi line item forecast model chang
page
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
exhibit wolf abbvi balanc sheet statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
page
incom statement except revenu initi good profit ens oper incom incom financ profit incom incom azn share mm margin product sale exclud good margin total total margin total margin pre-r total margin total margin total rate good profit ens incom incom incom outstand ww- ww- ww- onglyza ww- ww ww bydureon ww- lokelma aka hyperkalemia ww- roxadustat hif-phi ckd ww- ww total ww ww ww eklira/tudorza ww bevespi ww fasenra asthma ww total ww ww ww ww ww ww imfinzi ww tremelimumab ww calquenc ww lynparza ww total total total ww ww movantik total ww ww ww anifrolumab- total pain infect total infect neurosci earli pipelin products- total w/w rx total total total
exhibit wolf astrazeneca balanc sheet statement
page
summari statement incom amort work non-cash cash provid short-term invest fix purchas purchas intang purchas non-curr asset made subsidiari non-control cash provid use invest purchas short term borrow cash provid use financ increas decreas begin rate end sheet cash equival market account incom tax current current properti plant goodwil tax current term tax benefit non-curr premium sharehold
page
incom statement except oper interest incom incom expens non-gaap share mm analysi good equiti outstand revenu w/pfe total total reyataz baraclud hcv total orencia orencia total matur product total earli stage factor- total
exhibit wolf bristol-my squibb balanc sheet statement
page
summari statement incom attribut non-controlling incom tax expens comp work cash provid purchas market ppe capit sale cash provid use invest purchas rate swap cash provid use financ exchang rate icreas decreas cash sheet cash equival market account current current properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold sharehold
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total prasugrel share total total primari taltz ixekizumab olumi baricitinib jak tanezumab anti-ngf pain galcanezumab anti-cgrp migrain total specialti total earli stage factor- total anim total
exhibit wolf eli lilli balanc sheet statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
page
incom statement revenu exclud sale revis profit revis revis revis ens revis profit revis financ inc/ profit revis revis incom revis interest viiv nvs/pfe chc sharehold revis pavg share million total margin revis revis revis oper margin revis rate revis margin revis profit revis revis revis profit revis incom revis incom revis revis outstand gbp laba/lama close definit stage sale includ
exhibit wolf glaxosmithklin balanc sheet statement
page
summari statement ventur dispos interest invest servic non- work net cash provid purchas properti plant purchas intang invest associ joint cash provid use invest treasuri shares/shar chang short term cash provid use financ exchang rate cash increas decreas end balanc sheet cash properti plant goodwil current term non-curr capit call premium earn profit loss sharehold minor employ total
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
product revenu daili total isentress remicad simponi zepati biosimilar viral vaccin proquad varivax pneumovax comvax pedvaxhib gardasil januvia dulera allergi women bridion keytruda onc pain product earli phase revenu incl lynparza total
exhibit wolf merck balanc sheet statement
page
flow statement incom incom distribut equiti incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
page
incom statement product incom net incom basic novn use outstand total product profit profit incom product incom outstand
page
product revenu cosentyx entresto canakinumab metabol ritalin group incl focalin siponimod aimovig kisqali kyrmiah sickl arcapta/onbrez breezhal seebri ultibro qmf laba/ ophthalmolog former alcon earli pipelin innov total
exhibit wolf novarti balanc sheet statement
page
flow statement incom cont amort revers non-cash flow work capit provis net current asset oper cash flow flow oper activ tangibl fix intang flow invest activ treasuri non-curr financi flow financ activ increas decreas cash sheet plant non-curr long term account current cash current treasuri share debt lt long-term long term account debt short-term liabil sharehold
page
incom statement incom outstand total profit profit incom
page
exhibit wolf pfizer balanc sheet statement
page
flow statement earn in-process sale impair restructur defer compens asset flow oper activ sale sale busi net invest flow invest activ chang short term repay long-term common dividend flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock cent par valu paid-in comprehens treasuri stock sharehold liabil sharehold
page
incom statement chf salessfr oper incomesfr revenuessfr sfr profitsfr distributionsfr profitsfr financi incom sfr financi expens -sfr financi income-sfr profitsfr taxessfr incomesfr incom rochesfr basic core sfr dilut core sfr outstand outstand product profit profit profit
page
product revenu chf ww incl sq form sfr wwsfr info wwsfr wwsfr ww incl sq form sfr wwsfr wwsfr wwsfr alectinib alki wwsfr cobimetinib mek inhibitor wwsfr atezolizumab wwsfr wwsfr recormon/epoginsfr oncologysfr total pharma bi-specif ixa/x wwsfr ocrelizumab ww sfr ww alz dz sfr ww alz dz sfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr ww parkinson sfr earli stage pipelin sfr pharma salessfr caresfr diagnost incl ind bu sfr diagnosticssfr diagnost ventana sfr diagnost salessfr total revenuessfr
exhibit wolf roch balanc sheet statement
page
flow statement chf incomesfr incomesfr costssfr taxessfr profitsfr ppesfr intangiblessfr gener operationssfr decreas work capitalsfr tax paidsfr flow oper activitivi cfo sfr ppe-sfr intang assets-sfr flow invest activ cfi -sfr decreas long-term debt-sfr equiti instrumentssfr decreas short-term borrowings-sfr paid-sfr paid-sfr flow financ activ cff -sfr effect currenc translat cashsfr increas decreas cash equiv sfr sheet chf assetssfr long-term assetssfr receiv tradesfr incom tax assetssfr securitiessfr equivalentssfr current assetssfr assetssfr debtsfr incom tax liabilitiessfr non-curr liabilitiessfr debtsfr payabl trade othersfr current liabilitiessfr liabilitiessfr capitalsfr earningssfr reserve-sfr equiti attribut rogsfr interestsfr equitysfr
page
incom statement except revenu current op inc /exp royalti incom profit/ loss assoc incom attrib minor interest oper financi incom associ non-control tax net euro excl select item share mil margin product incom tax share profit incom excl select outstand
page
exhibit wolf sanofi balanc sheet statement
page
summari statement net incom amort chang defer taxes- cash flow chang work capit work capit cash provid oper ppe capit software- acquisitions- chg loan non-curr financi assets- cash provid use invest activities- paid- chang short-term borrow chang long-term debt- chang capit stocks- financial- cash provid use financ activities- exchang rate equivalents- increas decreas end period sheet cash equival current financi asset account receiv inventori current asset current asset properti plant equip goodwil intang asset asset payabl current liabil term debt term debt tax liabil non-curr liabil liabil equiti interest minor sharehold sharehold equiti liabil sharehold equiti
